Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole
Aims Nocturnal acid breakthrough has been considered an unmet need of proton‐pump
inhibitors. Tegoprazan, a novel potassium‐competitive acid blocker, is expected to show …
inhibitors. Tegoprazan, a novel potassium‐competitive acid blocker, is expected to show …
Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ‐12420), a novel …
Background Tegoprazan (CJ‐12420) is a potassium‐competitive acid blocker (P‐CAB) with
therapeutic potential for gastro‐oesophageal reflux disease (GERD) by reversibly …
therapeutic potential for gastro‐oesophageal reflux disease (GERD) by reversibly …
Efficient dynamic bandwidth allocation for FSAN-compliant GPON
MS Han, H Yoo, BY Yoon, B Kim… - Journal of Optical …, 2008 - opg.optica.org
We suggest an immediate allocation with colorless grant (IACG) method for dynamic bandwidth
allocation of a gigabit passive optical network (GPON) system. The suggested method is …
allocation of a gigabit passive optical network (GPON) system. The suggested method is …
Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects
Background Potassium‐competitive acid blockers (P‐CABs) are emerging as novel treatments
for acid‐related disorders including gastroesophageal reflux disease. Tegoprazan and …
for acid‐related disorders including gastroesophageal reflux disease. Tegoprazan and …
Comparison of pharmacodynamics between tegoprazan and dexlansoprazole regarding nocturnal acid breakthrough: a randomized crossover study
…, YH Kim, SC Choi, S Kim, JY Nam, B Kim… - Gut and …, 2022 - pmc.ncbi.nlm.nih.gov
Background/Aims Tegoprazan, a novel potassium-competitive acid blocker, is expected to
overcome the limitations of proton pump inhibitors and effectively control nocturnal acid …
overcome the limitations of proton pump inhibitors and effectively control nocturnal acid …
Pharmacokinetics and pharmacodynamics of tegoprazan coadministered with amoxicillin and clarithromycin in healthy subjects
…, MC Chin, J Jung, J Lee, S Kim, B Kim… - The Journal of …, 2021 - Wiley Online Library
This clinical trial was conducted to evaluate the pharmacokinetics and pharmacodynamics
of tegoprazan when coadministered with amoxicillin/clarithromycin in healthy subjects. …
of tegoprazan when coadministered with amoxicillin/clarithromycin in healthy subjects. …
Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
…, J Sunwoo, N Shin, AR Kim, B Kim… - Clinical and …, 2021 - Wiley Online Library
Tegoprazan, a novel potassium‐competitive acid blocker, is used to treat acid‐related diseases.
However, there is no information on the pharmacokinetic (PK) and pharmacodynamic (…
However, there is no information on the pharmacokinetic (PK) and pharmacodynamic (…
Characterization of a novel anti-human TNF-α murine monoclonal antibody with high binding affinity and neutralizing activity
In order to develop an anti-human TNF-α mAb, mice were immunized with recombinant human
TNF-α. A murine mAb, TSK114, which showed the highest binding activity for human TNF-…
TNF-α. A murine mAb, TSK114, which showed the highest binding activity for human TNF-…
Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
…, IK Chung, IK Sung, JI Kim, JH Kim… - Alimentary …, 2019 - Wiley Online Library
Background Tegoprazan is a novel potassium‐competitive acid blocker that has a fast onset
of action and can control gastric pH for a prolonged period, which could offer clinical benefit …
of action and can control gastric pH for a prolonged period, which could offer clinical benefit …
Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan
S Han, HY Choi, YH Kim, JY Nam, B Kim, GS Song… - Clinical Therapeutics, 2021 - Elsevier
Purpose Tegoprazan is a potassium-competitive acid blocker (P-CAB) that is designed to
treat acid-related diseases through a fundamentally different mechanism than that of proton …
treat acid-related diseases through a fundamentally different mechanism than that of proton …